GCKD – Uniklinikum Erlangen

Uniklinikum Erlangen GCKD The Medical Clinic 4 – Nephrology and Hypertensiology at the University Hospital Erlangen represents a large research center for kidney diseases. It hosts the headquarter of the German Chronic Kidney Disease (GCKD) study, the worldwide largest CKD cohort study. The GCKD study has enrolled more than 5000 participants with CKD and has meanwhile followed them for more than 10 years. The study is designed to improve our understanding of the causes, variability and consequences of progressive kidney disease to identify new possibilities for diagnosis, prognostic stratification and therapy. Within the PRIME-CKD consortium GCKD will provide patient specimens for biomarker validation studies.

People involved in Prime-CKD

Kai-Uwe Eckardt (MD, Professor)

Kai-Uwe Eckardt (MD, Professor) is principal investigator of the GCKD study and full Professor at Charité, Berlin. He is a clinician scientist, qualified as physiologist and internist with a track record in both experimental and clinical research. His main research interests include the pathogenesis and progression of chronic kidney disease. Prof. Eckardt has also participated in large interventional trials in CKD patients and is since long actively involved in international efforts to optimise treatment strategies.

Mario Schiffer (MD, Professor)

Mario Schiffer (MD, Professor) is the director of the Medical Clinic 4 at the University Hospital Erlangen, Germany and member of the GCKD steering committee. He is a clinician scientist, qualified as nephrologist and internist with a track record of accomplishment in both experimental and clinical research. His main research interests are the identification of novel pathways in proteinuric human diseases like diabetes, glomerulonephritis and transplant glomerulopathy.

GCKD – Uniklinikum Erlangen

People involved in Prime-CKD

Kai-Uwe Eckardt (MD, Professor)

Mario Schiffer (MD, Professor)

Prof. Schneider (Researcher)

Dr. Meiselbach (GCKD study coordinator)

Links

EU FUNDING

CONTACT